Irinotecan Plus E7820 Versus FOLFIRI in Second-Line Therapy in Patients With Locally Advanced or Metastatic Colon or Rectal Cancer
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Clinical Trials Related to FOLFIRI
Related studies linked through entity extraction aliases.
A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With Metastatic Colorectal Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Regorafenib+FOLFIRI Versus Placebo+FOLFIRI as 2nd Line Tx in Metastatic Colorectal Cancer
- Status
- COMPLETED
- Phase
- PHASE2
4SC-201 (Resminostat) in Advanced Colorectal Carcinoma
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
FOLFOXIRI Compared With FOLFIRI for Metastatic Colorectal Cancer
- Status
- COMPLETED
- Phase
- PHASE3
FOLFIRI Alone Versus FOLFIRI Plus Bevacizumab Versus FOLFIRI Plus E7820 as Second-Line Therapy in Patients With Locally Advanced or Metastatic Colorectal Cancer
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Study of CS-1008 in Combination With FOLFIRI in Patients Who Have Failed Other Treatments
- Status
- COMPLETED
- Phase
- PHASE1
MEK Inhibitor MSC1936369B Plus FOLFIRI in Second Line K-Ras Mutated Metastatic Colorectal Cancer (mCRC)
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Prognostic Factors for Patients With Advanced Colorectal Cancer Treated With Cetuximab.
- Status
- COMPLETED
- Phase
- PHASE2
A Study of Vismodegib (GDC-0449) in Patients Treated With Vismodegib in a Previous Genentech-sponsored Phase I or II Cancer Study
- Status
- COMPLETED
- Phase
- PHASE2
Sorafenib and FOLFIRI Regimen in 2nd Colorectal Cancer (CRC) After Failure of Oxaliplatin Treatment
- Status
- UNKNOWN
- Phase
- PHASE2
Study Evaluating the Safety and Efficacy of FOLFIRI Plus Cetuximab or FOLFOX Plus Cetuximab as First-line Therapy in Subjects With KRAS Wild-type Metastatic Colorectal Cancer (APEC-Study)
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
A Phase 2, Randomized, Double Blind, Placebo Controlled Study of AMG 386 in Combination With FOLFIRI in Subjects With Previously Treated Metastatic Colorectal Carcinoma
- Status
- COMPLETED
- Phase
- PHASE2
Study of FOLFIRI Plus Cetuximab Plus IMO-2055 in Patients With Colorectal Cancer
- Status
- TERMINATED
- Phase
- PHASE1
A Study of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) With Concurrent Chemotherapy and Bevacizumab As First-Line Therapy for Metastatic Colorectal Cancer
- Status
- COMPLETED
- Phase
- PHASE2
A Study to Determine the Activity of Robatumumab (SCH 717454, MK-7454) in Participants With Relapsed or Recurrent Colorectal Cancer (P04721, MK-7454-003)
- Status
- COMPLETED
- Phase
- PHASE2
Panitumumab Plus FOLFIRI in First-line Treatment of Metastatic Colorectal Cancer
- Status
- COMPLETED
- Phase
- PHASE2
A Phase II, Double Blind Study of 2 Doses of ZACTIMA™(ZD6474) in Combination With FOLFIRI vs FOLFIRI Alone for the Treatment of Colorectal Cancer in Patients
- Status
- COMPLETED
- Phase
- PHASE2
Panitumumab Regimen Evaluation in Colorectal Cancer to Estimate Primary Response to Treatment
- Status
- COMPLETED
- Phase
- PHASE2
Metastatic Gastric Cancer FFCD 03-07
- Status
- COMPLETED
- Phase
- PHASE3